Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Celcuity Inc (CELC)

Celcuity Inc (CELC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,279,983
  • Shares Outstanding, K 46,271
  • Annual Sales, $ 0 K
  • Annual Income, $ -111,780 K
  • EBIT $ -159 M
  • EBITDA $ -158 M
  • 60-Month Beta 0.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 41.68

Options Overview Details

View History
  • Implied Volatility 78.81% (+0.77%)
  • Historical Volatility 35.37%
  • IV Percentile 55%
  • IV Rank 10.42%
  • IV High 317.42% on 07/25/25
  • IV Low 51.06% on 08/19/25
  • Expected Move (DTE 1) 6.39 (5.68%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 87
  • Volume Avg (30-Day) 1,302
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 35,749
  • Open Int (30-Day) 26,799
  • Expected Range 106.12 to 118.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.01
  • Number of Estimates 2
  • High Estimate -0.83
  • Low Estimate -1.20
  • Prior Year -0.85
  • Growth Rate Est. (year over year) -18.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
102.94 +9.29%
on 02/20/26
119.69 -6.00%
on 03/10/26
+6.80 (+6.43%)
since 02/18/26
3-Month
97.49 +15.41%
on 02/11/26
120.32 -6.49%
on 01/27/26
+13.35 (+13.46%)
since 12/18/25
52-Week
7.57 +1,386.26%
on 04/08/25
120.32 -6.49%
on 01/27/26
+102.42 (+1,015.06%)
since 03/18/25

Most Recent Stories

More News
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will...

CELC : 112.51 (-1.40%)
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus...

CELC : 112.51 (-1.40%)
Celcuity To Participate in Upcoming Investor Conferences

MINNEAPOLIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian...

CELC : 112.51 (-1.40%)
Celcuity Appoints Charles Romp to its Board of Directors

MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment...

CELC : 112.51 (-1.40%)
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation...

CELC : 112.51 (-1.40%)
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026 MINNEAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing...

CELC : 112.51 (-1.40%)
Novel Modalities Drive $668B Precision Oncology Expansion

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is projected to reach US$668.26 billion by 2034[1], as investors increasingly...

ONCY : 0.9605 (-3.06%)
PSTV : 0.2360 (-5.60%)
IMNM : 20.62 (-0.43%)
BCYC : 4.70 (-7.30%)
CELC : 112.51 (-1.40%)
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival (“PFS”) was 12.4 months with gedatolisib + palbociclib + fulvestrant (“gedatolisib...

CELC : 112.51 (-1.40%)
3 Stocks You’ll Wish You Bought Before 2026

These three up-and-coming stocks are delivering massive 2025 gains and may have more room to run as key catalysts unfold

DAVE : 206.09 (-1.95%)
CELC : 112.51 (-1.40%)
TDUP : 3.39 (-3.69%)
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract...

CELC : 112.51 (-1.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's...

See More

Key Turning Points

3rd Resistance Point 120.08
2nd Resistance Point 118.13
1st Resistance Point 115.32
Last Price 112.51
1st Support Level 110.56
2nd Support Level 108.61
3rd Support Level 105.80

See More

52-Week High 120.32
Last Price 112.51
Fibonacci 61.8% 77.25
Fibonacci 50% 63.94
Fibonacci 38.2% 50.64
52-Week Low 7.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar